+ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
+ ++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
+ ++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
+ ++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
+ ++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
+ \ No newline at end of file diff --git a/src/components/ELSI/ELSICard.vue b/src/components/ELSI/ELSICard.vue new file mode 100644 index 0000000..a4df828 --- /dev/null +++ b/src/components/ELSI/ELSICard.vue @@ -0,0 +1,16 @@ + + + +- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
- -- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
- -- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
+- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
- -- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
- -- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
- \ No newline at end of file diff --git a/src/components/ELSI/categories/Agriculture.vue b/src/components/ELSI/categories/Agriculture.vue new file mode 100644 index 0000000..71a6306 --- /dev/null +++ b/src/components/ELSI/categories/Agriculture.vue @@ -0,0 +1,30 @@ + + + ++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
++ This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. + In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application + clinically but there may still be ethical considerations and differences between different medical practitioners willingness to + administer a new drug to patients with little known long-term effects. +
+- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Biofilms can have beneficial uses in some cases, such as how the food industry uses them for water and wastewater treatment, plant health enhancement, and food product productivity (Olanbiwoninu & Popoola, 2022). + As a result, it would be detrimental to the food industry and those who work in it if enzymosomes carrying biofilm degrading enzymes were to come in contact with these biofilms. + This could impact the livelihoods of farmers and landowners, as well as the supply of food available to the larger population.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Any impact on the food industry could cause the general public to view this product in a negative light, resulting in wariness and resistance against its use. + Because this affects an industry essential to survival, this is more likely to elicit a negative response.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Rebuttal: It is not difficult to ensure that the production and use of enzymosomes remains far from key biofilms of the food industry. + A protocol for enzymosome “spills” or “leaks” can also be developed to minimize the impact of any enzymosomes on these biofilms.
- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Because there is potential for this project to be commercialized and it is based on a combination of pre-existing concepts, there is a concern over whether doing so will violate any intellectual property over the concepts involved. + Intellectual property is important because it helps to ensure that those involved in creating these concepts receive the credit for and benefits of their efforts. + Thus, it is important that any intellectual property involved is respected when commercializing any application of these concepts.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + If existing intellectual property is not properly respected, the resulting commercial product may face public backlash in addition to legal and ethical issues, + as it would be seen as trying to unfairly profit from the work of others.
- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + One possible application of the enzymosome is in healthcare to treat biofilms in patients, such as those with cystic fibrosis. + With the development of a new treatment, it is natural that the general public–both those receiving treatment and not–may have concerns about the possible short-term and long-term risks the project may pose, + and how safe it is for everyone that may directly or indirectly come in contact with it. + Particularly since our enzyme has a very general target of DNA, which is present everywhere and not just in affected patients, even individuals or things not intended to receive the treatment may also be affected. + So, it is necessary to consider how we can mitigate possible risks, and all possible groups that could be affected.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Patients could be worried about the risks of receiving a treatment involving our project and whether there are risks for individuals around them as well. + This apprehension could discourage individuals affected by cystic fibrosis from receiving treatment due to the potential risks outweighing the benefits, and other members of the general public + may disapprove if they are worried they themselves may be affected by secondhand effects.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Rebuttal: To mitigate concerns, we could regularly monitor patients after they have received treatment to see if any of the common symptoms of cystic fibrosis worsen (ie. severe cough, lung infections, etc.) during trials to ensure the safety of our product. + The monitoring would need to occur over a long period of time to also study possible long-term effects of treatment. We should also take care to monitor the effects on individuals in regular contact with patients (ie. family, friends, staff administering treatment, etc.) + to ensure there is no negative effect on them as well. Additionally, experimentation for how our enzymosomes perform in the presence of other non-target DNA to imitate how it functions in non-controlled conditions could be attempted to develop an idea of how our project + may indirectly affect the environment. If any side effects posing significant health concerns do arise, we would have to develop a treatment plan for patients and those around them before continuing to test or distribute our enzymosomes.
- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + As we prepare treatment for testing, it raises questions focused on the ethics of who should receive initial trials and treatment involving our enzymosomes. + Should we try to make it useful for as many people as possible or focus on treating certain demographics more effectively? If we are targeting certain groups, who and why? + What groups are disadvantaged during testing stages?
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Patients may be dissatisfied that some people are able to receive the test treatments and benefit first, and become frustrated with us and our research. There could also be negative reactions from regions that would struggle to receive treatment, + either they are too rural to be regularly monitored or low income and lack the necessary equipment.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Rebuttal: If we have to target certain demographics due to cost restraints for example, we can base our target demographic on the groups of people and regions most affected by bacterial biofilms. + This would allow us to immediately distribute our treatment to and assist as many people as possible who are the most impacted. This would also have the additional benefit of allowing us to conduct more trials and collect data studying the effectiveness of treatment. + We should also consider the ability of the community to benefit from treatment when considering which demographic to target for trials, so we should research whether there are certain demographics that are better suited for receiving initial trial stages of treatment, + or if there are others that are at a higher risk and more susceptible to being affected by negative side effects. + To combat the possibility of certain demographics perhaps being unable to receive the treatment we can also try to reach out to rural communities or low-income regions that are likely to have more difficulties accessing the treatment but would greatly benefit + (due to how long hospital stays and cost of treatment currently are for cystic fibrosis treatments). Also, during testing, we can still try to run trials on members of other groups outside our target demographic to see what adjustments should be made to ensure a diverse range of people can benefit, + and if any risks do arise we can investigate if all demographics are equally affected.
\ No newline at end of file diff --git a/src/components/ELSI/categories/Hospitals.vue b/src/components/ELSI/categories/Hospitals.vue index fdaa228..0b914f7 100644 --- a/src/components/ELSI/categories/Hospitals.vue +++ b/src/components/ELSI/categories/Hospitals.vue @@ -12,19 +12,10 @@ clinically but there may still be ethical considerations and differences between different medical practitioners willingness to administer a new drug to patients with little known long-term effects. -- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + A negative connotation amongst doctors and medical practitioners could lead to reduced willingness for patients to use the drug + in addition to it not being administered to patients that could potentially benefit from the treatment.
\ No newline at end of file diff --git a/src/components/ELSI/categories/ResearchFacilities.vue b/src/components/ELSI/categories/ResearchFacilities.vue index 02005df..12fa934 100644 --- a/src/components/ELSI/categories/ResearchFacilities.vue +++ b/src/components/ELSI/categories/ResearchFacilities.vue @@ -7,24 +7,13 @@- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + The concern with research facilities will be the impact of the waste products both on the people working with the enzymosomes in research facilities and for the environment as well. + The waste products that are produced must be monitored for potential health impacts on researchers as well as harmful effects they could have during disposal both to the facility and to the environment.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + There may be reluctance for labs in general to take on projects relating to enzymosomes if there are huge concerns for ethical implications of the product as a whole and on the environment. + If these concerns are made public then it would have an impact on the users of the product as well as they will be more reluctant to use a product that is ethically ambiguous.
\ No newline at end of file diff --git a/src/components/ELSI/categories/Universities.vue b/src/components/ELSI/categories/Universities.vue index 02005df..0e93a1f 100644 --- a/src/components/ELSI/categories/Universities.vue +++ b/src/components/ELSI/categories/Universities.vue @@ -7,24 +7,18 @@- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + In order to create enzymosomes, universities and research facilities must obtain materials from various sources, which are usually chemical suppliers. + Some of these suppliers may obtain these materials in a way that is considered unethical, such as through harming humans or other organisms. + Alternatively, the company itself may support unethical practices, meaning that purchasing their products would be indirectly supporting these practices.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + People dislike supporting unethically produced innovations, which may lead to backlash regardless of how beneficial the technology could be. + This may lead to boycotts and wariness of the product, lessening its positive impact.
-- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. + Rebuttal: A background check on material sources and suppliers can be easily performed to ensure that any materials used are ethically sound.
\ No newline at end of file From 22801fa478efd11ca5dd870d01b5bb40c237669a Mon Sep 17 00:00:00 2001 From: Daniel Pan <57362494+daniel-panhead@users.noreply.github.com> Date: Tue, 26 Sep 2023 15:08:49 -0700 Subject: [PATCH 08/20] Add citation for agriculture content --- src/components/ELSI/categories/Agriculture.vue | 3 +++ 1 file changed, 3 insertions(+) diff --git a/src/components/ELSI/categories/Agriculture.vue b/src/components/ELSI/categories/Agriculture.vue index 76192c5..6e61f47 100644 --- a/src/components/ELSI/categories/Agriculture.vue +++ b/src/components/ELSI/categories/Agriculture.vue @@ -21,5 +21,8 @@ Rebuttal: It is not difficult to ensure that the production and use of enzymosomes remains far from key biofilms of the food industry. A protocol for enzymosome “spills” or “leaks” can also be developed to minimize the impact of any enzymosomes on these biofilms. + +- Biofilms can have beneficial uses in some cases, such as how the food industry uses them for water and wastewater treatment, plant health enhancement, and food product productivity (Olanbiwoninu & Popoola, 2022). - As a result, it would be detrimental to the food industry and those who work in it if enzymosomes carrying biofilm degrading enzymes were to come in contact with these biofilms. - This could impact the livelihoods of farmers and landowners, as well as the supply of food available to the larger population. -
-- Any impact on the food industry could cause the general public to view this product in a negative light, resulting in wariness and resistance against its use. - Because this affects an industry essential to survival, this is more likely to elicit a negative response. -
-- Rebuttal: It is not difficult to ensure that the production and use of enzymosomes remains far from key biofilms of the food industry. - A protocol for enzymosome “spills” or “leaks” can also be developed to minimize the impact of any enzymosomes on these biofilms. -
++ Biofilms can have beneficial uses in some cases, such as how the food industry uses them for + water and wastewater treatment, plant health enhancement, and food product productivity + (Olanbiwoninu & Popoola, 2022). As a result, it would be detrimental to the food industry and + those who work in it if enzymosomes carrying biofilm degrading enzymes were to come in contact + with these biofilms. This could impact the livelihoods of farmers and landowners, as well as + the supply of food available to the larger population. +
++ Any impact on the food industry could cause the general public to view this product in a + negative light, resulting in wariness and resistance against its use. Because this affects an + industry essential to survival, this is more likely to elicit a negative response. +
++ Rebuttal: It is not difficult to ensure that the production and use of enzymosomes + remains far from key biofilms of the food industry. A protocol for enzymosome “spills” or + “leaks” can also be developed to minimize the impact of any enzymosomes on these biofilms. +
-- Because there is potential for this project to be commercialized and it is based on a combination of pre-existing concepts, there is a concern over whether doing so will violate any intellectual property over the concepts involved. - Intellectual property is important because it helps to ensure that those involved in creating these concepts receive the credit for and benefits of their efforts. - Thus, it is important that any intellectual property involved is respected when commercializing any application of these concepts. -
-- If existing intellectual property is not properly respected, the resulting commercial product may face public backlash in addition to legal and ethical issues, - as it would be seen as trying to unfairly profit from the work of others. -
-+ Because there is potential for this project to be commercialized and it is based on a + combination of pre-existing concepts, there is a concern over whether doing so will violate + any intellectual property over the concepts involved. Intellectual property is important + because it helps to ensure that those involved in creating these concepts receive the credit + for and benefits of their efforts. Thus, it is important that any intellectual property + involved is respected when commercializing any application of these concepts. +
++ If existing intellectual property is not properly respected, the resulting commercial product + may face public backlash in addition to legal and ethical issues, as it would be seen as + trying to unfairly profit from the work of others. +
+- One possible application of the enzymosome is in healthcare to treat biofilms in patients, such as those with cystic fibrosis. - With the development of a new treatment, it is natural that the general public–both those receiving treatment and not–may have concerns about the possible short-term and long-term risks the project may pose, - and how safe it is for everyone that may directly or indirectly come in contact with it. - Particularly since our enzyme has a very general target of DNA, which is present everywhere and not just in affected patients, even individuals or things not intended to receive the treatment may also be affected. - So, it is necessary to consider how we can mitigate possible risks, and all possible groups that could be affected. -
-- Patients could be worried about the risks of receiving a treatment involving our project and whether there are risks for individuals around them as well. - This apprehension could discourage individuals affected by cystic fibrosis from receiving treatment due to the potential risks outweighing the benefits, and other members of the general public - may disapprove if they are worried they themselves may be affected by secondhand effects. -
-- Rebuttal: To mitigate concerns, we could regularly monitor patients after they have received treatment to see if any of the common symptoms of cystic fibrosis worsen (ie. severe cough, lung infections, etc.) during trials to ensure the safety of our product. - The monitoring would need to occur over a long period of time to also study possible long-term effects of treatment. We should also take care to monitor the effects on individuals in regular contact with patients (ie. family, friends, staff administering treatment, etc.) - to ensure there is no negative effect on them as well. Additionally, experimentation for how our enzymosomes perform in the presence of other non-target DNA to imitate how it functions in non-controlled conditions could be attempted to develop an idea of how our project - may indirectly affect the environment. If any side effects posing significant health concerns do arise, we would have to develop a treatment plan for patients and those around them before continuing to test or distribute our enzymosomes. -
-+ One possible application of the enzymosome is in healthcare to treat biofilms in patients, + such as those with cystic fibrosis. With the development of a new treatment, it is natural + that the general public–both those receiving treatment and not–may have concerns about the + possible short-term and long-term risks the project may pose, and how safe it is for everyone + that may directly or indirectly come in contact with it. Particularly since our enzyme has a + very general target of DNA, which is present everywhere and not just in affected patients, + even individuals or things not intended to receive the treatment may also be affected. So, it + is necessary to consider how we can mitigate possible risks, and all possible groups that + could be affected. +
++ Patients could be worried about the risks of receiving a treatment involving our project and + whether there are risks for individuals around them as well. This apprehension could + discourage individuals affected by cystic fibrosis from receiving treatment due to the + potential risks outweighing the benefits, and other members of the general public may + disapprove if they are worried they themselves may be affected by secondhand effects. +
++ Rebuttal: To mitigate concerns, we could regularly monitor patients after they have + received treatment to see if any of the common symptoms of cystic fibrosis worsen (ie. severe + cough, lung infections, etc.) during trials to ensure the safety of our product. The + monitoring would need to occur over a long period of time to also study possible long-term + effects of treatment. We should also take care to monitor the effects on individuals in + regular contact with patients (ie. family, friends, staff administering treatment, etc.) to + ensure there is no negative effect on them as well. Additionally, experimentation for how our + enzymosomes perform in the presence of other non-target DNA to imitate how it functions in + non-controlled conditions could be attempted to develop an idea of how our project may + indirectly affect the environment. If any side effects posing significant health concerns do + arise, we would have to develop a treatment plan for patients and those around them before + continuing to test or distribute our enzymosomes. +
+- As we prepare treatment for testing, it raises questions focused on the ethics of who should receive initial trials and treatment involving our enzymosomes. - Should we try to make it useful for as many people as possible or focus on treating certain demographics more effectively? If we are targeting certain groups, who and why? - What groups are disadvantaged during testing stages? -
-- Patients may be dissatisfied that some people are able to receive the test treatments and benefit first, and become frustrated with us and our research. There could also be negative reactions from regions that would struggle to receive treatment, - either they are too rural to be regularly monitored or low income and lack the necessary equipment. -
-- Rebuttal: If we have to target certain demographics due to cost restraints for example, we can base our target demographic on the groups of people and regions most affected by bacterial biofilms. - This would allow us to immediately distribute our treatment to and assist as many people as possible who are the most impacted. This would also have the additional benefit of allowing us to conduct more trials and collect data studying the effectiveness of treatment. - We should also consider the ability of the community to benefit from treatment when considering which demographic to target for trials, so we should research whether there are certain demographics that are better suited for receiving initial trial stages of treatment, - or if there are others that are at a higher risk and more susceptible to being affected by negative side effects. - To combat the possibility of certain demographics perhaps being unable to receive the treatment we can also try to reach out to rural communities or low-income regions that are likely to have more difficulties accessing the treatment but would greatly benefit - (due to how long hospital stays and cost of treatment currently are for cystic fibrosis treatments). Also, during testing, we can still try to run trials on members of other groups outside our target demographic to see what adjustments should be made to ensure a diverse range of people can benefit, - and if any risks do arise we can investigate if all demographics are equally affected. -
-+ As we prepare treatment for testing, it raises questions focused on the ethics of who should + receive initial trials and treatment involving our enzymosomes. Should we try to make it + useful for as many people as possible or focus on treating certain demographics more + effectively? If we are targeting certain groups, who and why? What groups are disadvantaged + during testing stages? +
++ Patients may be dissatisfied that some people are able to receive the test treatments and + benefit first, and become frustrated with us and our research. There could also be negative + reactions from regions that would struggle to receive treatment, either they are too rural to + be regularly monitored or low income and lack the necessary equipment. +
++ Rebuttal: If we have to target certain demographics due to cost restraints for example, + we can base our target demographic on the groups of people and regions most affected by + bacterial biofilms. This would allow us to immediately distribute our treatment to and assist + as many people as possible who are the most impacted. This would also have the additional + benefit of allowing us to conduct more trials and collect data studying the effectiveness of + treatment. We should also consider the ability of the community to benefit from treatment when + considering which demographic to target for trials, so we should research whether there are + certain demographics that are better suited for receiving initial trial stages of treatment, + or if there are others that are at a higher risk and more susceptible to being affected by + negative side effects. To combat the possibility of certain demographics perhaps being unable + to receive the treatment we can also try to reach out to rural communities or low-income + regions that are likely to have more difficulties accessing the treatment but would greatly + benefit (due to how long hospital stays and cost of treatment currently are for cystic + fibrosis treatments). Also, during testing, we can still try to run trials on members of other + groups outside our target demographic to see what adjustments should be made to ensure a + diverse range of people can benefit, and if any risks do arise we can investigate if all + demographics are equally affected. +
+- This includes the ethical implications of using a new drug that has not been tested for long-term side effects on patients. - In order to be able to use the enzymosomes to degrade bacterial biofilms in patients, there will be testing prior to application - clinically but there may still be ethical considerations and differences between different medical practitioners willingness to - administer a new drug to patients with little known long-term effects. -
-- A negative connotation amongst doctors and medical practitioners could lead to reduced willingness for patients to use the drug - in addition to it not being administered to patients that could potentially benefit from the treatment. -
-+ This includes the ethical implications of using a new drug that has not been tested for + long-term side effects on patients. In order to be able to use the enzymosomes to degrade + bacterial biofilms in patients, there will be testing prior to application clinically but + there may still be ethical considerations and differences between different medical + practitioners willingness to administer a new drug to patients with little known long-term + effects. +
++ A negative connotation amongst doctors and medical practitioners could lead to reduced + willingness for patients to use the drug in addition to it not being administered to patients + that could potentially benefit from the treatment. +
+- The concern with research facilities will be the impact of the waste products both on the people working with the enzymosomes in research facilities and for the environment as well. - The waste products that are produced must be monitored for potential health impacts on researchers as well as harmful effects they could have during disposal both to the facility and to the environment. -
-- There may be reluctance for labs in general to take on projects relating to enzymosomes if there are huge concerns for ethical implications of the product as a whole and on the environment. - If these concerns are made public then it would have an impact on the users of the product as well as they will be more reluctant to use a product that is ethically ambiguous. -
-+ The concern with research facilities will be the impact of the waste products both on the + people working with the enzymosomes in research facilities and for the environment as well. + The waste products that are produced must be monitored for potential health impacts on + researchers as well as harmful effects they could have during disposal both to the facility + and to the environment. +
++ There may be reluctance for labs in general to take on projects relating to enzymosomes if + there are huge concerns for ethical implications of the product as a whole and on the + environment. If these concerns are made public then it would have an impact on the users of + the product as well as they will be more reluctant to use a product that is ethically + ambiguous. +
+- In order to create enzymosomes, universities and research facilities must obtain materials from various sources, which are usually chemical suppliers. - Some of these suppliers may obtain these materials in a way that is considered unethical, such as through harming humans or other organisms. - Alternatively, the company itself may support unethical practices, meaning that purchasing their products would be indirectly supporting these practices. -
-- People dislike supporting unethically produced innovations, which may lead to backlash regardless of how beneficial the technology could be. - This may lead to boycotts and wariness of the product, lessening its positive impact. -
-- Rebuttal: A background check on material sources and suppliers can be easily performed to ensure that any materials used are ethically sound. -
-+ In order to create enzymosomes, universities and research facilities must obtain materials + from various sources, which are usually chemical suppliers. Some of these suppliers may obtain + these materials in a way that is considered unethical, such as through harming humans or other + organisms. Alternatively, the company itself may support unethical practices, meaning that + purchasing their products would be indirectly supporting these practices. +
++ People dislike supporting unethically produced innovations, which may lead to backlash + regardless of how beneficial the technology could be. This may lead to boycotts and wariness + of the product, lessening its positive impact. +
++ Rebuttal: A background check on material sources and suppliers can be easily performed + to ensure that any materials used are ethically sound. +
+Body
+Body
Body
+Body
Body
+Body
+ ``` -Note that the default font color has been set to `text-grey-50`. \ No newline at end of file +Note that the default font color has been set to `text-grey-50`. diff --git a/src/views/HomeView.vue b/src/views/HomeView.vue index ccd1f19..805dc52 100644 --- a/src/views/HomeView.vue +++ b/src/views/HomeView.vue @@ -110,7 +110,9 @@ const scrollToTop = () => { @apply w-full bg-no-repeat; background-image: url('../assets/homepage_bg_rot_mobile.png'), url('../assets/homepage_bg_top_mobile.png'); - background-position: -2% 5%, right 6%; + background-position: + -2% 5%, + right 6%; } @media only screen and (min-width: 1024px) { @@ -118,7 +120,10 @@ const scrollToTop = () => { @apply w-full bg-no-repeat; background-image: url('../assets/homepage_bg_rot.png'), url('../assets/homepage_bg_top.png'), url('../assets/homepage_bg.png'); - background-position: -2% 5%, right 5%, right 25%; + background-position: + -2% 5%, + right 5%, + right 25%; } } diff --git a/tailwind.config.js b/tailwind.config.js index b56b85c..c1875cd 100644 --- a/tailwind.config.js +++ b/tailwind.config.js @@ -22,14 +22,14 @@ module.exports = { fontWeight: '600' } ], - 'title': [ + title: [ '5rem', { fontWeight: '600' } ], 'subtitle-sm': ['1.2rem'], - 'subtitle': ['1.35rem'] + subtitle: ['1.35rem'] } } }, From b57f7925837376394639a52d663d9fd006c2d422 Mon Sep 17 00:00:00 2001 From: Daniel Pan <57362494+daniel-panhead@users.noreply.github.com> Date: Sat, 7 Oct 2023 14:39:58 -0700 Subject: [PATCH 17/20] Add hand graphic to elsi --- src/components/ELSI/HandSVG.vue | 359 ++++++++++++++++++++++++++++++++ src/views/ELSIView.vue | 6 +- 2 files changed, 364 insertions(+), 1 deletion(-) create mode 100644 src/components/ELSI/HandSVG.vue diff --git a/src/components/ELSI/HandSVG.vue b/src/components/ELSI/HandSVG.vue new file mode 100644 index 0000000..3bdbeff --- /dev/null +++ b/src/components/ELSI/HandSVG.vue @@ -0,0 +1,359 @@ + + + + \ No newline at end of file diff --git a/src/views/ELSIView.vue b/src/views/ELSIView.vue index bd360af..b94023a 100644 --- a/src/views/ELSIView.vue +++ b/src/views/ELSIView.vue @@ -8,6 +8,7 @@ import Home from '@/components/ELSI/categories/Home.vue' import ResearchFacilities from '@/components/ELSI/categories/ResearchFacilities.vue' import HospitalLab from '@/components/ELSI/categories/HospitalLab.vue' import Businesses from '@/components/ELSI/categories/Businesses.vue' +import HandSVG from '@/components/ELSI/HandSVG.vue' const categories = [ { @@ -56,7 +57,7 @@ const setSelection = (num: number) => {